166.27 0.00 (0.00%)
After hours: 5:53PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||164.65 - 169.69|
|52 Week Range||142.81 - 256.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.88 (1.72%)|
|1y Target Est||N/A|
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
This weekend's Barron's shows why one key analyst has a contrarian view on the direction that health care costs are headed. Other featured articles examine the prospects for pharmaceutical company facing ...
Looks can be deceiving when it comes to the drugmaker Allergan. New competition to its top product, Botox, and the surprise loss of patent exclusivity for its second biggest, the dry-eye treatment Restasis, have left investors with worry lines. The valuation is low enough that most of the bad news surrounding Allergan appear already priced in.
Drugmaker Mylan N.V. (NASDAQ:MYL) has garnered quite a bit of bullish attention since the beginning of the month. MYL stock is up more than 4% so far in March, beating the benchmark S&P 500 Index’s gain of about 1.4%. First, Mylan reported better than expected earnings on March 1 and it announced a competitor to Allergan plc Ordinary Sharess (NYSE:AGN) Botox treatment.
Allergan plc Ordinary Shares (NYSE: AGN ) continued its two-week, 16-percent rebound Wednesday, and RBC Capital Markets anticipates 28 percent of additional upside . The Rating Analyst Randall Stanicky ...
Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.
In 4Q17, Merck’s (MRK) Emend generated revenues of $143 million, which reflected a ~1% decline on a YoY (year-over-year) basis but a 4% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Emend reported revenues of $85 million and $58 million, respectively, compared with $90 million and $53 million in 4Q16, which reflected a ~6% decline and an 8% rise, respectively, YoY. In fiscal 2017, Emend generated revenues of $556 million, compared with $549 million in 2016, which reflected a ~1% rise YoY.
The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines
Allergan Plc Chief Executive Officer Brent Saunders received $32.8 million of compensation for 2017, a year when shares of the drugmaker slumped.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
It is one of the world’s most recognised pharmaceuticals brands, but Botox — the wrinkle treatment beloved by celebrities and more — is starting to show signs of age. Allergan first won approval for the ...
Smart investors actively track the moves made by the titans of the hedge fund world, such as billionaire activist investor Paul Singer of Elliott Management. They know that these hedge funds manage billions of dollars’ worth of investors’ money and do extensive and costly research on stocks before they buy them. However, that doesn’t mean […]
Revance Therapeutics Inc (NASDAQ: RVNC ) has dropped 9 percent since the start of the year, but it's begun a path to redemption through a new, respected advocate. The Rating Goldman Sachs analysts Dana ...
Adamis’ Symjepi was billed as an EpiPen competitor, but the company’s search for a commercialization partner has prevented it from coming to market.
Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.
Allergan tanked to a five-year low Thursday after Mylan and Revance announced their plan to bring a Botox copycat to the market.